{"id":"naloxone-intranasal","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Anxiety"}]},"_chembl":{"chemblId":"CHEMBL3249799","moleculeType":"Small molecule","molecularWeight":"327.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Naloxone works by rapidly displacing opioids from their receptors in the brain and spinal cord, restoring normal breathing and circulation. This is achieved through competitive inhibition, where naloxone binds to the same receptors as opioids, preventing them from exerting their effects. As a result, naloxone can quickly reverse the life-threatening symptoms of opioid overdose.","oneSentence":"Naloxone reverses opioid overdose by competitively binding to opioid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:16.686Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of opioid overdose"}]},"trialDetails":[{"nctId":"NCT04851301","phase":"PHASE1, PHASE2","title":"Neural Mechanisms of Immersive Virtual Reality in Chronic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-11-01","conditions":"Pain, Virtual Reality, Placebo","enrollment":259},{"nctId":"NCT04129138","phase":"","title":"Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-18","conditions":"Caregiver, Patient","enrollment":182},{"nctId":"NCT03608163","phase":"PHASE4","title":"Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2019-01-08","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness","enrollment":4},{"nctId":"NCT06306391","phase":"PHASE1","title":"Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2024-03-05","conditions":"Healthy","enrollment":8},{"nctId":"NCT04828005","phase":"PHASE1","title":"Pharmacodynamic Evaluation of Intranasal Nalmefene","status":"COMPLETED","sponsor":"Opiant Pharmaceuticals Inc","startDate":"2021-03-30","conditions":"Pharmacodynamic","enrollment":84},{"nctId":"NCT06719986","phase":"PHASE1","title":"Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2022-10-03","conditions":"Opioid Overdose","enrollment":24},{"nctId":"NCT03897998","phase":"PHASE2","title":"Neural Correlates of Hypoalgesia Driven by Observation","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-11-01","conditions":"Pain, Virtual Reality, Placebo","enrollment":182},{"nctId":"NCT06633900","phase":"PHASE2, PHASE3","title":"Naltrexone for Overdose Prevention","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-04-10","conditions":"Overdose Accidental","enrollment":100},{"nctId":"NCT05114460","phase":"PHASE2","title":"Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-11-01","conditions":"Opioid Overdose","enrollment":2},{"nctId":"NCT05338632","phase":"PHASE1","title":"Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2022-06-24","conditions":"Opioid Induced Respiratory Depression, Chronic Opioid Use","enrollment":24},{"nctId":"NCT05877118","phase":"NA","title":"Improving Availability of Intranasal Naloxone","status":"RECRUITING","sponsor":"Hartford Hospital","startDate":"2024-03-01","conditions":"Opioid Overdose","enrollment":84},{"nctId":"NCT04764630","phase":"PHASE1","title":"Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2021-03-01","conditions":"Healthy Subjects, Opioid Antagonist, Pharmacokinetics","enrollment":21},{"nctId":"NCT03149770","phase":"PHASE2","title":"Naloxone, Hypoglycemia and Exercise","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2017-09-18","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT05377255","phase":"PHASE1","title":"Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2022-03-28","conditions":"Opioid Overdose","enrollment":24},{"nctId":"NCT03309449","phase":"NA","title":"A Usability Assessment of Naloxone by Community Members","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2016-08","conditions":"Drug Overdose","enrollment":138},{"nctId":"NCT05072249","phase":"","title":"European Cohort Study of the Effectiveness of Take Home Naloxone","status":"UNKNOWN","sponsor":"King's College London","startDate":"2021-06-08","conditions":"Opioid Overdose","enrollment":6000},{"nctId":"NCT05363501","phase":"PHASE1","title":"Pharmacokinetic Evaluation of a New Naloxone Nasal Swab, Naloxone Nasal Spray, and Intramuscular Naloxone Injection in Healthy Volunteers","status":"COMPLETED","sponsor":"Pocket Naloxone Corp","startDate":"2021-01-21","conditions":"Opioid Overdose","enrollment":76},{"nctId":"NCT01939444","phase":"PHASE2","title":"A Pilot Study of the Bioavailability of Nasal Naloxone","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2013-08","conditions":"Drug Overdose","enrollment":5},{"nctId":"NCT03518021","phase":"PHASE3","title":"Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2018-05-15","conditions":"Overdose, Drug Abuse","enrollment":286},{"nctId":"NCT03851731","phase":"PHASE1","title":"Evaluation of Intranasal Naltrexone and Naloxone","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2015-10-05","conditions":"Opioid-use Disorder","enrollment":12},{"nctId":"NCT04025671","phase":"NA","title":"A Usability Assessment of Naloxone Administration by Untrained Community Members","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2017-08-23","conditions":"Harm Reduction, Opioid-use Disorder, Naloxone","enrollment":208},{"nctId":"NCT03430180","phase":"PHASE2","title":"Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder","status":"UNKNOWN","sponsor":"Finnish Institute for Health and Welfare","startDate":"2018-02-22","conditions":"Pathological Gambling, Gambling Disorder, Opioid Antagonist","enrollment":126},{"nctId":"NCT02307721","phase":"PHASE1, PHASE2","title":"Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2014-12","conditions":"Drug Overdose","enrollment":12},{"nctId":"NCT03610672","phase":"NA","title":"Mobile Intervention for Young Opioid Users","status":"UNKNOWN","sponsor":"National Development and Research Institutes, Inc.","startDate":"2017-09-15","conditions":"Opioid-Related Disorders","enrollment":64},{"nctId":"NCT03386591","phase":"PHASE1","title":"Comparison of Naloxone Pharmacokinetics","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2018-01-03","conditions":"Opioid-use Disorder","enrollment":30},{"nctId":"NCT01760473","phase":"PHASE3","title":"Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2009-05","conditions":"Heroin Dependence","enrollment":27},{"nctId":"NCT02158117","phase":"PHASE1","title":"Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2014-03","conditions":"Drug Overdose","enrollment":12},{"nctId":"NCT02598856","phase":"PHASE1","title":"Bioavailability of Nasal Naloxone and Injected Naloxone Compared","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-03","conditions":"Drug Overdose","enrollment":22},{"nctId":"NCT02572089","phase":"PHASE1","title":"Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2014-10","conditions":"Drug Overdose, Opioid-Related Disorders","enrollment":30},{"nctId":"NCT02750748","phase":"PHASE1","title":"Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2016-07","conditions":"Opioid-Related Disorders","enrollment":14},{"nctId":"NCT01912573","phase":"PHASE4","title":"Nasal Naloxone for Narcotic Overdose","status":"UNKNOWN","sponsor":"Judith Feinberg","startDate":"2013-09","conditions":"Drug Overdose","enrollment":236},{"nctId":"NCT01622504","phase":"PHASE1","title":"Naloxone Nasal Spray Pharmacokinetic Study","status":"UNKNOWN","sponsor":"Mitovie Pharma Ltd","startDate":"2012-06","conditions":"Opioid Overdose","enrollment":6},{"nctId":"NCT01595867","phase":"PHASE1","title":"Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Narcotic Abuse, Opioid-related Disorders, Analgesia","enrollment":33},{"nctId":"NCT01567670","phase":"PHASE2, PHASE3","title":"Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray","status":"UNKNOWN","sponsor":"Lightlake Sinclair Ltd.","startDate":"2011-08","conditions":"Binge Eating Disorder","enrollment":138},{"nctId":"NCT01293058","phase":"PHASE2","title":"Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid Overdose","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2007-03","conditions":"Morphinan Opioid Overdose","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":298,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Naloxone, intranasal","genericName":"Naloxone, intranasal","companyName":"Norwegian University of Science and Technology","companyId":"norwegian-university-of-science-and-technology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxone reverses opioid overdose by competitively binding to opioid receptors. Used for Reversal of opioid overdose.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}